Point72 (DIFC)’s Inovio Pharmaceuticals INO Stock Holding History

Point72 (DIFC)’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,600	Closed	-$5.29K	–	1514
2025 Q2	$5.29K	Buy	+2,600	New	+$4.98K	﹤0.01%	1374

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 (DIFC)'s INO Position: Q3 2025 in Review

Point72 (DIFC) sold out of Inovio Pharmaceuticals (INO) in Q3 2025, closing a stake of 2,600 shares — an estimated $5.29K sold.

Point72 (DIFC) first reported a position in INO in Q2 2025 and held it in 1 quarter. The position peaked at $5.29K in Q2 2025. 99 funds tracked by Wall St. Rank hold INO as of Q3 2025.

Point72 (DIFC) reported no remaining Inovio Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Point72 (DIFC) sold 2,600 Inovio Pharmaceuticals shares in Q3 2025, an estimated $5.29K.
Point72 (DIFC) first reported a position in Inovio Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Point72 (DIFC)'s Inovio Pharmaceuticals position peaked at $5.29K in Q2 2025.
99 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.